Literature DB >> 22115474

Re: Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed?

Samir S Taneja.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22115474     DOI： 10.1016/j.juro.2010.12.087

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  1 in total

1.  Pyk2 promotes tumor progression in renal cell carcinoma.

Authors:  Tangliang Zhao; Yi Bao; Xin Lu; Yi He; Xinxin Gan; Jianchao Wang; Bing Liu; Linhui Wang
Journal:  Oncol Lett       Date:  2018-09-06       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.